Rapid Benzodiazepine Detoxification Using Flumazenil - 1

This study has been completed.

Sponsors and Collaborators:	National Institute on Drug Abuse (NIDA) Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000246

Purpose

The purpose of this study is to verify the hypothesis that the benzodiazepine antagonist, flumazenil, will reduce acute benzodiazepine withdrawal.

Condition	Intervention	Phase
Substance-Related Disorders	Drug: Flumazenil	Phase II

Drug Information available for: Flumazenil

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Rapid Benzodiazepine Detoxification Using Flumazenil

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Estimated Enrollment:

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000246

Locations

United States, Connecticut
Yale University, Psychiatry
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators

Principal Investigator:

Scott Woods, M.D.

Yale University

More Information

Study ID Numbers:	NIDA-08265-1, R01-08265-1
Study First Received:	September 20, 1999
Last Updated:	August 16, 2005
ClinicalTrials.gov Identifier:	NCT00000246
Health Authority:	United States: Federal Government

Study placed in the following topic categories:

Flumazenil
Mental Disorders
Substance-Related Disorders
Disorders of Environmental Origin

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
GABA Modulators
Physiological Effects of Drugs

GABA Agents
Protective Agents
Pharmacologic Actions
Antidotes

ClinicalTrials.gov processed this record on January 15, 2009